A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 981 shares of CRSP stock, worth $40,162. This represents 0.0% of its overall portfolio holdings.

Number of Shares
981
Previous 1,038 5.49%
Holding current value
$40,162
Previous $56,000 17.86%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$44.62 - $62.75 $2,543 - $3,576
-57 Reduced 5.49%
981 $46,000
Q2 2024

Aug 14, 2024

BUY
$51.17 - $68.18 $358 - $477
7 Added 0.68%
1,038 $56,000
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $62,550 - $91,882
1,031 New
1,031 $70.3 Million
Q4 2023

Aug 14, 2024

SELL
$38.62 - $72.18 $3,900 - $7,290
-101 Reduced 11.21%
800 $50.1 Million
Q2 2023

Aug 14, 2024

SELL
$43.47 - $67.77 $1,825 - $2,846
-42 Reduced 4.45%
901 $50.6 Million
Q1 2023

Aug 14, 2024

BUY
$41.0 - $56.12 $17,425 - $23,851
425 Added 82.05%
943 $42.7 Million
Q4 2022

Aug 14, 2024

SELL
$39.19 - $65.67 $12,736 - $21,342
-325 Reduced 38.55%
518 $21.1 Million
Q3 2022

Aug 14, 2024

BUY
$61.1 - $83.78 $6,110 - $8,378
100 Added 13.46%
843 $55.1 Million
Q2 2022

Aug 14, 2024

SELL
$43.23 - $73.83 $3,674 - $6,275
-85 Reduced 10.27%
743 $45.2 Million
Q1 2022

Aug 14, 2024

SELL
$53.19 - $79.24 $11,169 - $16,640
-210 Reduced 20.23%
828 $52 Million
Q4 2021

Aug 30, 2024

SELL
$70.09 - $111.29 $3,854 - $6,120
-55 Reduced 5.3%
983 $74.5 Million
Q3 2021

Aug 30, 2024

SELL
$110.2 - $156.64 $24,244 - $34,460
-220 Reduced 17.49%
1,038 $116 Million
Q2 2021

Aug 30, 2024

BUY
$100.84 - $161.89 $22,184 - $35,615
220 Added 21.19%
1,258 $204 Million
Q1 2021

Aug 30, 2024

BUY
$110.72 - $210.04 $19,818 - $37,597
179 Added 16.13%
1,289 $157 Million
Q4 2020

Aug 30, 2024

BUY
$79.67 - $173.23 $8,524 - $18,535
107 Added 10.67%
1,110 $170 Million
Q3 2020

Aug 30, 2024

SELL
$78.5 - $100.64 $258,893 - $331,910
-3,298 Reduced 76.68%
1,003 $83.9 Million
Q2 2020

Aug 30, 2024

SELL
$38.5 - $76.05 $798,374 - $1.58 Million
-20,737 Reduced 82.82%
4,301 $317 Million
Q1 2020

Aug 30, 2024

BUY
$33.68 - $62.53 $793,433 - $1.47 Million
23,558 Added 1591.76%
25,038 $1.07 Billion
Q4 2019

Aug 30, 2024

SELL
$36.68 - $73.13 $3,301 - $6,581
-90 Reduced 5.73%
1,480 $90.1 Million
Q2 2019

Aug 30, 2024

SELL
$35.45 - $48.2 $1,063 - $1,446
-30 Reduced 1.88%
1,570 $73.9 Million
Q1 2019

Aug 30, 2024

SELL
$28.02 - $40.87 $2,802 - $4,086
-100 Reduced 5.88%
1,600 $57.2 Million
Q4 2018

Aug 30, 2024

BUY
$22.73 - $42.34 $15,047 - $28,029
662 Added 63.78%
1,700 $48.6 Million
Q3 2018

Aug 30, 2024

SELL
$44.35 - $65.71 $13,305 - $19,712
-300 Reduced 6.48%
4,330 $192 Million
Q2 2018

Aug 30, 2024

BUY
$42.62 - $73.59 $150,448 - $259,772
3,530 Added 320.91%
4,630 $272 Million
Q1 2018

Aug 30, 2024

BUY
$23.52 - $58.17 $19,992 - $49,444
850 Added 340.0%
1,100 $50.3 Million
Q3 2017

Aug 30, 2024

SELL
$16.75 - $20.66 $9,212 - $11,363
-550 Reduced 68.75%
250 $4.47 Million
Q2 2017

Aug 30, 2024

BUY
N/A
152 Added 23.46%
800 $12.8 Million
Q1 2017

Aug 30, 2024

SELL
N/A
-390
648 $14.1 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.19B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.